HVC
Healthcare Value Capital Portfolio holdings
AUM
$38.5M
This Quarter Return
+2.6%
1 Year Return
+22.29%
3 Year Return
+31.09%
5 Year Return
+125.72%
10 Year Return
–
AUM
$21.8M
AUM Growth
+$21.8M
(-12%)
Cap. Flow
-$411K
Cap. Flow
% of AUM
-1.88%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
2
Increased
2
Reduced
–
Closed
2
Top Buys
| 1 |
Gilead Sciences
GILD
|
$3.25M |
| 2 |
Viking Therapeutics
VKTX
|
$1.49M |
| 3 |
AGN
Allergan plc
AGN
|
$1.46M |
| 4 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$711K |
Top Sells
| 1 |
Standard BioTools
LAB
|
$3.88M |
| 2 |
ProShares UltraShort NASDAQ Biotechnology
BIS
|
$3.45M |
Sector Composition
| 1 | Healthcare | 96.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $4.39M | 16.92% | 30,000 +10,000 | +50% | +$1.46M |
|
2
GSK
GSK
$79.9B
| $4.18M | 16.1% | 100,000 | – | – |
|
|
TYME
3
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $3.83M | 14.75% | 2,175,000 | – | – |
|
|
4
Gilead Sciences
GILD
$140B
| $3.25M | 12.53% | +50,000 | New | +$3.25M |
|
|
5
Viking Therapeutics
VKTX
$3.04B
| $2.49M | 9.57% | 250,000 +150,000 | +150% | +$1.49M |
|
|
NVLN
6
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $2.21M | 8.53% | 1,800,000 | – | – |
|
|
ATRS
7
DELISTED
Antares Pharma, Inc.
ATRS
| $758K | 2.92% | 250,000 | – | – |
|
|
ADMS
8
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $711K | 2.74% | +100,000 | New | +$711K |
|
|
9
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.47M
| – | – | -150,000 | Closed | -$3.45M |
|
|
10
Standard BioTools
LAB
$481M
| – | – | -450,000 | Closed | -$3.88M |
|
11
Ligand Pharmaceuticals
LGND
$3.15B
| – | – | 0 | – | – |
|
|
LCI
12
DELISTED
Lannett Company, Inc.
LCI
| – | – | 0 | – | – |
|